Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma: A Pilot Study

NCT03972046 is registered in ClinicalTrials.gov with TriHealth Inc. as lead sponsor.

NCT NCT03972046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03972046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma: A Pilot Study
Lead sponsor
TriHealth Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
June 24, 2019
Completion date
February 3, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf gene mutation, melanoma (skin), melanoma stage iiib-ivm1a, metastasis skin, tumor skin